Plexpress Announces Collaboration With Admescope
For more information about how TRAC could boost the efficiency of your drug discovery pipeline, please visit www.plexpress.com. For more information about the new Admescope services utilising TRAC, please email info@admescope.com or view the detailed TRAC announcement on the Admescope website.
Reference:
1. FDA Guidance for Industry Report (Feb 2012): Drug Interaction Studies Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations
About Plexpress
Plexpress was established as a spinoff from the Finnish Technology Research Center VTT in 2007. Including R&D at VTT, the company’s TRAC technology has been developed continuously for nearly 10 years and it has been documented in over 15 publications. The technology was originally developed for demanding bioprocess applications, which required a very robust solution for gene expression analysis. Since starting operations in 2008, the company has carried out over 50 projects using the TRAC technology in the fields of pharmaceutical development and academic research.
For further information see: www.plexpress.com
About Admescope
Admescope Ltd is an ADME CRO located in Oulu, Finland. The Admescope team has planned and conducted more than 750 ADME-related research projects for a high number of European biotech & pharma companies, and has published about 80 scientific papers in the field. The key expertise of the Admescope team centres around in vitro & in vivo drug metabolism, including metabolite profiling & identification using various LC/MS based techniques, drug-drug interactions and quantitative bioanalysis.
For further information see: http://www.admescope.com/